ArticleJTCVS structural and endovascular2025
Mitral valve surgery post-transcatheter aortic valve replacement: A 10-year, single-center, retrospective analysis.
Article in JTCVS structural and endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A decade of cardiac surgery after transcatheter aortic valve replacement: Short-term clinical outcomes at a high-volume center.JTCVS structural and endovascular · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cardiac operations after transcatheter aortic valve replacement (TAVR) are complex procedures with high morbidity and mortality. We sought to determine the outcomes of mitral valve surgery in patients with previous TAVR. Methods: Among 2339 patients who underwent mitral valve surgery at our institution between July 2014 and July 2024, a retrospective, descriptive analysis was performed on 19 consecutive patients with a history of TAVR requiring mitral valve surgery. Results: Mean age was 73.1 ± 9.5 years. The median (interquartile range) time since TAVR was 1 year (1, 3). The indication for mitral valve surgery was active infective endocarditis in 4 patients (21%), and degenerative disease in the remaining. The average Society of Thoracic Surgeons predicted risk of mortality was 12.0 ± 9.3%, with 6 (31.6%) urgent and 2 (10.5%) emergent operations. Nine patients (47.3%) had history of previous cardiac surgery. Mitral valve repair was performed in 1 patient, whereas replacement with a bioprosthetic valve in all other cases. Transcatheter valve explant was necessary in 10 operations (52.6%), and 13 patients had a concomitant procedure. The primary end point of all-cause mortality at 30 days was met in 5 patients (26.3%), 3 of whom underwent TAVR explant. One patient (5.3%) suffered a stroke. Median crossclamp and cardiopulmonary bypass times were 144 (106, 189) and 214 (155, 253) minutes, respectively. Postoperative dialysis was required in 4 (21.1%). One patient required a reintervention and 3 were re-hospitalized after discharge. Conclusions: Mitral valve surgery in the presence of TAVR is uncommon but carries a high risk of mortality and morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.